ERBB2 and neoplasm: Current developments of bispecific antibodies and CAR-T cells targeting Her2 and EGFR, respectively, have shown that tumor selectivity can be enhanced by lowering the affinity and enforcing the avidity of the antibody; thus, T cell triggering becomes only effective at high antigen density [21, 22].